Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
NCT ID: NCT05317819
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
300 participants
INTERVENTIONAL
2022-03-14
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Efficacy will be determined by overall survival, progression free survival, pharmacodynamics (peripheral blood arginine and citrulline levels) and immunogenicity (antibodies to ADI-PEG 20).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug: ADI-PEG 20
Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
ADI-PEG20
Treatment for hepatocellular carcinoma
Drug: Placebo
Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
Placebo
Treatment for hepatocellular carcinoma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADI-PEG20
Treatment for hepatocellular carcinoma
Placebo
Treatment for hepatocellular carcinoma
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Prior treatment with at least 1 systemic agent for Child-Pugh A subjects. However, Child-Pugh B7 subjects without prior systemic treatment may be enrolled, if they are not eligible for any approved systemic therapies (e.g., due to financial factors).
3. Plasma arginine ≥ 78 μM at pre-screening visit.
4. Measurable disease using RECIST 1.1 (Appendix A). At least 1 measurable lesion must be present. Subjects who have received local-regional therapies are eligible, provided that they have either a target lesion which has not been treated with local therapy and/or the target lesion(s) within the field of the local regional therapy has shown an increase of ≥ 20% in size. Local-regional therapy must be completed at least 4 weeks prior to the baseline CT scan.
5. Child-Pugh (cirrhosis status) score class A-B7 (Appendix C).
6. Barcelona Cancer of the Liver (BCLC) stage C (Appendix B)
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment (Appendix D).
8. Expected survival of at least 3 months.
9. Age \>18 years.
10. Fully recovered from prior surgery, radiation, or chemotherapy, and none within 2 weeks prior to week 1 visit. Liver biopsy for HCC confirmation is allowed.
11. Female subjects and male subjects must be asked to use appropriate contraception for both the male and female for the duration of the study and for 35 days after last dose of ADI-PEG 20/placebo. Male partners of female subjects and female partners of male subjects must agree to use two forms of contraception or agree to refrain from intercourse for the duration of the study if they are of childbearing potential. Females of childbearing potential must not be pregnant at the start of the study, and a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study. If positive HCG pregnancy test, further evaluation to rule out pregnancy must be performed according to GCP before this subject is deemed eligible. Females not of childbearing potential must be post-menopausal (defined as cessation of regular menstrual period for at least 12 months).
12. Informed consent must be obtained prior to study initiation.
13. No concurrent investigational studies are allowed.
14. Total bilirubin \< 3.0 mg/dL and no evidence of bile obstruction.
15. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 x upper limit of normal range.
16. Serum albumin level ≥ 3.0 g/dl.
17. Prothrombin time (PT)-international normalized ratio (INR): PT \<3 seconds above control or INR \<1.7.
18. Absolute neutrophil count (ANC) \>1,500/µL.
19. Platelets \>50,000/µL.
20. Serum uric acid ≤ 8 mg/dL (with or without medication control).
21. Serum creatinine ≤ 1.5 x the upper limit of normal range, or, if serum creatinine \>1.5 x the upper limit of normal range, then the creatinine clearance must be ≥ 40 mL/min.
22. Subjects with active hepatitis B or C on anti-viremic compounds may remain on such treatment, except for interferon.
23. Encephalopathy - none or mild (grade 1 or 2, by Child-Pugh classification); lactulose of other supportive care allowed.
24. Ascites - absent or slight (by Child-Pugh classification); diuretic therapy allowed.
Exclusion Criteria
2. Prior allograft transplantation including liver transplantation.
3. Subjects who have not fully recovered from toxicities associated with previous HCC loco-regional or systemic therapies, except for Grade 1 alopecia.
4. Serious infection requiring treatment with intravenous, systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment.
5. Pregnancy or lactation.
6. Expected non-compliance.
7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, or psychiatric illness, social situations that would limit compliance with study requirements.
8. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the investigator will not affect patient outcome.
9. Subjects who had been treated with ADI-PEG 20 previously.
10. History of uncontrolled seizure disorder not related to underlying cancer.
11. Allergy to pegylated compounds.
12. Allergy to E. coli drug products (such as GMCSF).
13. Bleeding esophageal or gastric varices within the prior three months, except if banded or treated.
14. Uncontrolled ascites (defined as not easily controlled with diuretic treatment).
15. Having received any blood transfusion, blood component preparation, erythropoietin, albumin preparation, or granulocyte colony stimulating factors (G-CSF) within 7 days prior to screening laboratories or after screening laboratories have been obtained until week 1 visit.
16. Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Polaris Group
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John S Bomalaski
Role: STUDY_DIRECTOR
Polaris Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhua Christian Hospital (CCH)
Changhua, , Taiwan
Ditmanson Medical Foundation Chiayi Christian Hospital (CYCH)
Chiayi City, , Taiwan
Chang Gung Medical Foundation-Chia-Yi (CGMF-CY)
Chiayi City, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
Kaohsiung City, , Taiwan
Chang Gung Medical Foundation-Kaohsiung(CGMF-KS)
Kaohsiung City, , Taiwan
Chi Mei Medical Center (CMMC-YK)
Tainan, , Taiwan
Chi Mei Hospital, Liouying (CMMC-LY)
Tainan, , Taiwan
Chang Gung Medical Foundation-Linkou (CGMF-LK)
Taoyuan District, , Taiwan
Bach Mai Hospital
Hanoi, , Vietnam
K Hospital
Hà Nội, , Vietnam
Hue Central Hospital
Huế, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yu-Chun Hsu
Role: primary
Chu-Kuang Chou
Role: primary
Te-Sheng Chang
Role: primary
Ming-Lung Yu
Role: primary
Sheng-Nan Lu
Role: primary
Hung-Chang Wu
Role: primary
Shang-Wen Chen
Role: primary
Chau-Ting Yeh
Role: primary
Nguyen Quang Hung
Role: primary
Tran Thang
Role: primary
Dao Van Tu
Role: backup
Phan Hai Thanh
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
POLARIS2021-001
Identifier Type: -
Identifier Source: org_study_id